Metagenomi, Inc. Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
Metagenomi, Inc. (MGX) reported its Q3 2025 financial results, showing a net loss of $20.4 million, up from $18.8 million a year prior. Revenue from collaborations fell to $8.7 million from $11.5 million, while operating expenses decreased to $31.5 million. The company holds $32.8 million in cash and $151.3 million in marketable securities. R&D expenses were $25.3 million as Metagenomi focuses on advancing its genetic medicine programs and genome editing technology for future growth.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments